文献速递泌尿生殖妇产影像技术与安全MRCT

盆腔放疗中纯MRI工作流程的逐步评估:可行性与实践实施

Step-by-step assessment of MRI-only workflow in pelvic radiotherapy: feasibility and practical implementation.
PubMed 文献 · Radiol Med · 2025-12-02

纳入55例盆腔癌症患者,逐步评估纯MRI放疗流程(MRI单独勾画、合成CT剂量计算、CBCT-MRI引导定位),并与标准CT-MRI流程对比。结果显示该流程贯穿各放疗阶段且兼容多种设备;前列腺和宫颈MRI勾画一致性优(DSC分别为0.948±0.028和0.940±0.015),直肠和前列腺床一致性在观察者间变异范围内;CT与合成CT计划剂量学无显著差异(p>0.05),CBCT-MRI定位误差与CBCT-CT相当。结论认为通过定制化协议,纯MRI盆腔放疗流程临床可行。

要点

  • 前列腺和宫颈MRI单独勾画与标准流程一致性优(DSC分别为0.948±0.028和0.940±0.015)。
  • 直肠和前列腺床DSC分别为0.696±0.037和0.689±0.047,落在观察者间变异范围内。
  • CT与合成CT计划剂量学无显著差异(p>0.05),全身3%/3 mm和2%/2 mm标准中位伽马通过率分别为99.0%和97.9%。

核心结论

  • 通过针对靶区和危及器官勾画、MRI扫描仪设置与固定、序列选择、合成CT剂量计算验证及CBCT-MRI匹配可靠性的定制化协议,纯MRI盆腔放疗流程临床可行。

研究设计与样本

  • 纳入55例盆腔癌症患者,均接受基于CT-MRI共配准的标准放疗流程,涉及多种成像扫描仪、治疗计划系统和直线加速器;对每例患者逐步开发完全整合的纯MRI方法,包括MRI单独勾画、合成CT生成与剂量计算、CBCT-MRI引导定位,并与标准流程对比评估靶区勾画(DSC和HD)、剂量计算(DVH参数和伽马分析)及每日患者定位(CBCT-CT与CBCT-MRI配准)。

关键影像表现/征象

  • 前列腺MRI单独勾画与标准流程一致性优,DSC=0.948±0.028。
  • 宫颈MRI单独勾画与标准流程一致性优,DSC=0.940±0.015。
  • 直肠勾画一致性DSC=0.696±0.037,前列腺床DSC=0.689±0.047,均落在观察者间变异范围内。

诊断标准与关键数值

  • 靶区勾画一致性以DSC和HD评估,前列腺DSC=0.948±0.028,宫颈DSC=0.940±0.015,直肠DSC=0.696±0.037,前列腺床DSC=0.689±0.047。
  • 剂量学比较CT与合成CT计划无显著差异(p>0.05),全身中位伽马通过率3%/3 mm标准为99.0%,2%/2 mm标准为97.9%。
  • CBCT-MRI配准定位误差与CBCT-CT相当。

临床应用与阅片要点

  • 纯MRI流程可用于盆腔放疗各阶段,并兼容多种成像系统、治疗计划系统和直线加速器。
  • 前列腺和宫颈的MRI单独勾画与标准流程高度一致,直肠和前列腺床的一致性在观察者间变异范围内。
  • 合成CT计划与CT计划剂量学无显著差异,CBCT-MRI定位误差与CBCT-CT相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Magnetic resonance imaging-only (MRI-only) radiotherapy workflow capitalizes on the superior soft tissue contrast of MRI while eliminating computed tomography-MRI (CT-MRI) registration uncertainties. Most existing studies focus on optimizing individual components of this workflow, i.e., synthetic CT (sCT) generation, dose calculation accuracy, and the reliability of MRI-based patient positioning, while often neglecting comprehensive evaluation of the whole clinical process and its interdependent technical requirements.

METHODS: A total of 55 pelvic cancer patients, who underwent the standard radiotherapy workflow based on CT-MRI co-registration and involving a variety of imaging scanners, treatment planning systems (TPSs), and linear accelerators (LINACs), were included. For each patient, a fully integrated MRI-only approach was developed through a step-by-step evaluation of the different radiotherapy phases, including MRI-alone delineation, sCT generation with dose calculation, and cone beam CT-MRI (CBCT-MRI)-guided positioning. Comparative evaluations with the standard workflow were performed for target segmentation (dice similarity coefficient [DSC] and Hausdorff distance [HD]), dose calculation (DVH parameters and gamma analysis), and daily patient positioning (CBCT-CT versus CBCT-MRI registrations).

RESULTS: The proposed MRI-only workflow is applicable throughout all radiotherapy phases and compatible across multiple imaging systems, treatment planning systems, and linear accelerators. MRI-only delineation showed excellent agreement for the prostate (DSC = 0.948 ± 0.028) and cervix (DSC = 0.940 ± 0.015), whereas contour agreement for the rectum and prostate bed (DSC = 0.696 ± 0.037 and 0.689 ± 0.047, respectively) fell within the range of inter-observer variability. Dosimetric comparisons revealed no significant differences between CT- and sCT-based plans (p > 0.05), with median gamma pass rates of 99.0% and 97.9% for the whole body using 3%/3 mm and 2%/2 mm criteria, respectively. CBCT-MRI registration indicated positioning errors comparable to CBCT-CT.

CONCLUSION: MRI-only pelvic radiotherapy workflows are clinically feasible through customized protocols for target and OAR segmentation, MRI scanner setup and immobilization, sequence selection, sCT-based dose calculation validation, and CBCT-MRI matching reliability.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Xin X, Liu M, Li J, et al. Step-by-step assessment of MRI-only workflow in pelvic radiotherapy: feasibility and practical implementation. Radiol Med. 2025. PMID: 41331541. doi:10.1007/s11547-025-02160-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。